DOCSLIB.ORG

ASCO's Honest Broker

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ASCO's Honest Broker WEEK OF APRIL 21, 2014 BioCentury THE BERNSTEIN REPORT ON BIOBUSINESS Volume 22 • Number 16 • Page A1 of 19 Politics, Policy & Law ASCO’s honest broker By Steve Usdin BioCentury This Week Washington Editor A new access program and registry Cover Story Regulation developed by the American Society of Clinical Oncology to facilitate use of off- Honest Brokers — ASCO is developing Pain Politics — FDA Commissioner Mar- label cancer drugs could serve as a model an initiative to facilitate off-label access to garet Hamburg responds to critics of the for independent bodies that could manage targeted cancer therapies. If successful, the agency’s decision to approve Zogenix’s early access to experimental therapies, even system could serve as a model for third- Zohydro and warns about consequences though ASCO itself is not tackling compas- party bodies that could manage early for the integrity of science-based regula- sionate use. access to experimental therapies. tion./A10 ASCO’s initiative is designed to match off-label targeted cancer therapies to indi- Product Discovery & Development Finance vidual patients likely to benefit based on the genomic profile of their tumors, while col- CAR Hits Pothole — Adverse events led Ebb & Flow — Double-dippers defer lecting data about new uses for approved to protocol revisions in Sloan Kettering’s follow-on plans. Snake eyes for Cytos. drugs. trial of CD19-targeted CAR T cells. But Kaleo’s royalty deal. Epirus makes it move. “We should develop programs to make partner Juno Therapeutics and other CAR Steve Harr’s jump to Juno. Also: ALK- it easier to access drugs, but require more players don’t think this indicates a class Abello; Medivir; ThromboGenics; detailed reporting of outcomes, which is just effect./A5 Topotarget; Zogenix, et al./A12 the opposite of the current situation,” CMO Richard Schilsky told BioCentury. “Doing Emerging Company Profile Featured links this week/A11 so would provide treatment options to pa- Stock charts & tables/A19 tients in need and allow us to learn from all Mediating Rare Metabolism — Minoryx these patient experiences.” Company index/A7 both identifies novel chaperones and Like programs that grant early access to repurposes drugs to treat inherited metabolic experimental medicine, or compassionate diseases./A8 access, ASCO plans to limit its off-label Dynamiting Complement — True North’s initiative to patients who are not eligible for TM TNT009 inhibits an upstream target in the BioCentury 100 Indicators See next page classical complement pathway that could lead Week ended 4/18/14 to greater efficacy and an improved safety PRICES VOLUME profile relative to other complement inhibi- 4734.53 772.6M shrs tors./A9 up 1% dn 32% FDA’S PAIN One Month to Amsterdam Hamburg Talks Zohydro The 15th Bio€quity Europe is almost here, featuring the 7th annual BioCentury-Ernst & Young face-off. www.biocenturytv.com See the agenda following A19. See Program Notes on A5 rEVOLUTION Coming New York Calling Only two weeks until the rEVOLUTION Join the 21st meeting of NewsMakers in the Biotech Industry in New York. Symposium kicks off in Boston. Call for Presenting Companies on A13. See announcement following A19. BioCentury, THE BERNSTEIN REPORT ON BIOBUSINESS APRIL 21, 2014 PAGE A2 OF 19 Politics, Policy & Law, sion, that decision has to be made according from previous page “We should develop pro- to prespecified guidelines,” he said. “It has grams to make it easier to to be transparent, and as objective as pos- trials and who have no alternatives. sible — and people have to understand A central feature of the program is the access drugs, but require going in there will be some cases that will be establishment of an honest broker to make more detailed reporting of rejected.” decisions about the allocation of targeted therapies and to collect and analyze out- outcomes, which is just Support needed comes data. the opposite of the If the project is successful for off-label Drug companies will be asked to supply therapies, it could inspire similar schemes current situation.” off-label drugs at no cost, and insurance based on honest brokers affiliated with companies will be asked to pay for all other medical specialty societies that would serve Richard Schilsky, ASCO treatment expenses, Schilsky said. In return, as intermediaries between drug companies drug companies and payers would benefit and patients seeking early access to exper- even for experts,” he added. from the generation of data about off-label imental medicines. Physicians would submit a genomic pro- uses. PhRMA, BIO and their member com- file of a patient’s tumor from a CLIA-certified Schilsky has approached six pharma- panies, as well as patient organizations and lab, along with a proposed treatment plan ceutical companies to discuss the project. congressional staff, are all engaged in sepa- and request for off-label use of a targeted “All have expressed interest in the idea. rate discussions — primarily behind closed therapy, to an honest broker. The dosing None said they are definitely in,” he said. doors — about creating new policies to and regimen would be consistent with label- “No one has said no.” facilitate equitable early access to experi- ing for approved indications. Schilsky said he also has presented the mental therapies. To facilitate such requests, ASCO is concept to “a couple of insurance compa- As BioCentury proposed in a March 31 considering establishing an Internet-based nies. The general response has been: ‘We Commentary, the creation of independent “tumor board” of clinical oncologists and are OK paying for the healthcare costs as third parties is one of several options under molecular pathologists that would review long as we don’t have to pay for the expen- consideration. genomic test results and provide advice to sive drugs.’” To be successful, early access policies physicians, including potential treatment Schilsky also has discussed the concept will have to be aligned with several social options. with senior FDA officials. and scientific trends: social media-fueled The honest broker would review the “FDA feels that if something like this was patient empowerment; the development of application. For approved applications, the set up, it would enhance their understand- highly effective targeted therapies made honest broker would arrange for shipment ing of how these drugs are being used. FDA possible by the integration of molecular of a three-month supply of the drug. The may turn out to be a champion of this kind diagnostics into drug development and clin- patient’s response would be evaluated and, of approach,” he said. ical practice; and a “right to try” movement if appropriate, additional supplies would be Schilsky said ASCO hasn’t determined that is gaining traction among state and dispensed. how much the project will cost or how federal lawmakers. Schilsky said he is “writing a clinical much demand there will be. protocol for what will essentially be an “We plan to start this as a pilot project observational study.” with a limited number of physician practices Access and registry The protocol will be “for patients who scattered around the country, with as many According to Schilsky, ASCO’s program have exhausted all treatment options, but who drugs as we can get into the program was prompted by the realization that many have reasonable performance status, so they initially,” he said. “We want to see if this is oncologists lack the expertise required to have a meaningful chance of benefiting from feasible, if we can we get the drugs to make treatment decisions based on genomic therapy if benefit can be derived.” patients in a reasonable period of time, if test results, as well as the difficulty patients In addition to validating treatment plans, there are any significant patient benefits face in getting reimbursement for off-label the honest broker would maintain a registry from the approach, and if can we get the prescriptions. with information about patient characteris- necessary data from doctors.” “I’m reacting to the rapid penetration of tics and outcomes. ASCO hopes to get the pilot running genetic profiling in the cancer patient pop- ASCO is speaking with several for- and before year end. ulation, with many comprehensive cancer not-for profit entities that could serve as the centers, community hospitals, and commer- honest broker, Schilsky said. cial labs setting up to do multiplex testing,” He noted that clarity about the rules will Pivot point Schilsky said. Interpreting tests results to be key to making an honest broker accept- In a paper describing the program in determine whether a specific genomic vari- able to patients and the public. Nature Reviews Clinical Oncology this month, ant is clinically actionable is “challenging “Any time a third party makes a deci- Schilsky mentioned the possibility of includ- ing investigational drugs. But he told Bio- Century ASCO has decided to stick with approved drugs. This Week in SciBX “It was a question of not biting off more than I could chew. Once you get into Contaminating Cancer Genomes — Two European teams have pinpointed a DNA- investigational drugs, you get into a higher protective enzyme as a chemically tractable target whose inhibition kills cancer cells by level of complexity regarding human sub- accelerating DNA damage. SciBX Table of Contents, A3. See next page BioCentury, THE BERNSTEIN REPORT ON BIOBUSINESS APRIL 21, 2014 PAGE A3 OF 19 Politics, Policy & Law, from previous page ject participation and regulatory oversight,” he said. “There are at least 25 marketed targeted anticancer treatments SciBX This Week that hit 15 or so different genetic targets,” Schilsky added. “We already have a good starting point of the universe of marketed drugs ANALYSIS without having to get into investigational drugs.” ASCO’s project is inspired in part by the growing sophistication COVER STORY of patients who read Contaminating cancer genomes about targeted ther- Two European teams have pinpointed a DNA-protective apies on the Internet “Science is changing, enzyme as a chemically tractable target whose inhibition and request access kills cancer cells by accelerating DNA damage.
Load more

Recommended publications
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Chapter Four – TRPA1 Channels: Chemical and Temperature Sensitivity
    CHAPTER FOUR TRPA1 Channels: Chemical and Temperature Sensitivity Willem J. Laursen1,2, Sviatoslav N. Bagriantsev1,* and Elena O. Gracheva1,2,* 1Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA 2Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT, USA *Corresponding author: E-mail: [email protected], [email protected] Contents 1. Introduction 90 2. Activation and Regulation of TRPA1 by Chemical Compounds 91 2.1 Chemical activation of TRPA1 by covalent modification 91 2.2 Noncovalent activation of TRPA1 97 2.3 Receptor-operated activation of TRPA1 99 3. Temperature Sensitivity of TRPA1 101 3.1 TRPA1 in mammals 101 3.2 TRPA1 in insects and worms 103 3.3 TRPA1 in fish, birds, reptiles, and amphibians 103 3.4 TRPA1: Molecular mechanism of temperature sensitivity 104 Acknowledgments 107 References 107 Abstract Transient receptor potential ankyrin 1 (TRPA1) is a polymodal excitatory ion channel found in sensory neurons of different organisms, ranging from worms to humans. Since its discovery as an uncharacterized transmembrane protein in human fibroblasts, TRPA1 has become one of the most intensively studied ion channels. Its function has been linked to regulation of heat and cold perception, mechanosensitivity, hearing, inflam- mation, pain, circadian rhythms, chemoreception, and other processes. Some of these proposed functions remain controversial, while others have gathered considerable experimental support. A truly polymodal ion channel, TRPA1 is activated by various stimuli, including electrophilic chemicals, oxygen, temperature, and mechanical force, yet the molecular mechanism of TRPA1 gating remains obscure. In this review, we discuss recent advances in the understanding of TRPA1 physiology, pharmacology, and molecular function.
    [Show full text]
  • The Emerging Role of Transient Receptor Potential Channels in Chronic Lung Disease
    BACK TO BASICS | TRANSIENT RECEPTOR POTENTIAL CHANNELS IN CHRONIC LUNG DISEASE The emerging role of transient receptor potential channels in chronic lung disease Maria G. Belvisi and Mark A. Birrell Affiliation: Respiratory Pharmacology Group, Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK. Correspondence: Maria G. Belvisi, Respiratory Pharmacology Group, Airway Disease Section, National Heart and Lung Institute, Imperial College, Exhibition Road, London SW7 2AZ, UK. E-mail: [email protected] @ERSpublications Transient receptor potential channels are emerging as novel targets for chronic lung diseases with a high unmet need http://ow.ly/GHeR30b3hIy Cite this article as: Belvisi MG, Birrell MA. The emerging role of transient receptor potential channels in chronic lung disease. Eur Respir J 2017; 50: 1601357 [https://doi.org/10.1183/13993003.01357-2016]. ABSTRACT Chronic lung diseases such as asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis are a major and increasing global health burden with a high unmet need. Drug discovery efforts in this area have been largely disappointing and so new therapeutic targets are needed. Transient receptor potential ion channels are emerging as possible therapeutic targets, given their widespread expression in the lung, their role in the modulation of inflammatory and structural changes and in the production of respiratory symptoms, such as bronchospasm and cough, seen in chronic lung disease. Received: Jan 08 2017 | Accepted after revision: April 14 2017 Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com Copyright ©ERS 2017 https://doi.org/10.1183/13993003.01357-2016 Eur Respir J 2017; 50: 1601357 TRANSIENT RECEPTOR POTENTIAL CHANNELS IN CHRONIC LUNG DISEASE | M.G.
    [Show full text]
  • Nerve Agent - Lntellipedia Page 1 Of9 Doc ID : 6637155 (U) Nerve Agent
    This document is made available through the declassification efforts and research of John Greenewald, Jr., creator of: The Black Vault The Black Vault is the largest online Freedom of Information Act (FOIA) document clearinghouse in the world. The research efforts here are responsible for the declassification of MILLIONS of pages released by the U.S. Government & Military. Discover the Truth at: http://www.theblackvault.com Nerve Agent - lntellipedia Page 1 of9 Doc ID : 6637155 (U) Nerve Agent UNCLASSIFIED From lntellipedia Nerve Agents (also known as nerve gases, though these chemicals are liquid at room temperature) are a class of phosphorus-containing organic chemicals (organophosphates) that disrupt the mechanism by which nerves transfer messages to organs. The disruption is caused by blocking acetylcholinesterase, an enzyme that normally relaxes the activity of acetylcholine, a neurotransmitter. ...--------- --- -·---- - --- -·-- --- --- Contents • 1 Overview • 2 Biological Effects • 2.1 Mechanism of Action • 2.2 Antidotes • 3 Classes • 3.1 G-Series • 3.2 V-Series • 3.3 Novichok Agents • 3.4 Insecticides • 4 History • 4.1 The Discovery ofNerve Agents • 4.2 The Nazi Mass Production ofTabun • 4.3 Nerve Agents in Nazi Germany • 4.4 The Secret Gets Out • 4.5 Since World War II • 4.6 Ocean Disposal of Chemical Weapons • 5 Popular Culture • 6 References and External Links --------------- ----·-- - Overview As chemical weapons, they are classified as weapons of mass destruction by the United Nations according to UN Resolution 687, and their production and stockpiling was outlawed by the Chemical Weapons Convention of 1993; the Chemical Weapons Convention officially took effect on April 291997. Poisoning by a nerve agent leads to contraction of pupils, profuse salivation, convulsions, involuntary urination and defecation, and eventual death by asphyxiation as control is lost over respiratory muscles.
    [Show full text]
  • * * * Chemical Agent * * * Instructor's Manual
    If you have issues viewing or accessing this file contact us at NCJRS.gov. · --. -----;-:-.. -----:-~------ '~~~v:~r.·t..~ ._.,.. ~Q" .._L_~ •.• ~,,,,,.'.,J-· .. f.\...('.1..-":I- f1 tn\. ~ L. " .:,"."~ .. ,. • ~ \::'J\.,;;)\ rl~ lL/{PS-'1 J National Institute of Corrections Community Corrections Division * * * CHEMICAL AGENT * * * INSTRUCTOR'S MANUAL J. RICHARD FAULKNER, JR. CORRECTIONAL PROGRAM SPECIALIST NATIONAL INSTITUTE OF CORRECTIONS WASIHNGTON, DC 20534 202-307-3106 - ext.138 , ' • 146592 U.S. Department of Justice National Institute of Justice This document has been reproduced exactly as received from the person or organization originating it. Points of view or opinions stated In tl]!::; document are those of the authors and do not necessarily represent the official position or policies of the National Institute of Justice. Permission to reproduce this "'"P 'J' ... material has been granted by Public Domain/NrC u.s. Department of Justice to the National Criminal Justice Reference Service (NCJRS). • Further reproduction outside of the NCJRS system reqllires permission of the f ._kt owner, • . : . , u.s. Deparbnent of Justice • National mstimte of Corrections Wtulringttm, DC 20534 CHEMICAL AGENTS Dangerous conditions that are present in communities have raised the level of awareness of officers. In many jurisdictions, officers have demanded more training in self protection and the authority to carry lethal weapons. This concern is a real one and administrators are having to address issues of officer safety. The problem is not a simple one that can be solved with a new policy. Because this involves safety, in fact the very lives of staff, the matter is extremely serious. Training must be adopted to fit policy and not violate the goals, scope and mission of the agency.
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List
    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
    [Show full text]
  • Nitrous Oxide (N2O) Isotopic Composition in the Troposphere: Instrumentation, Observations at Mace Head, Ireland, and Regional Modeling
    Nitrous oxide (N2O) isotopic composition in the troposphere: instrumentation, observations at Mace Head, Ireland, and regional modeling by Katherine Ellison Potter B.S. Chemistry & Environmental Science College of William and Mary, 2004 SUBMITTED TO THE DEPARTMENT OF EARTH, ATMOSPHERIC, AND PLANETARY SCIENCES IN PARTIAL FULFULLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN CLIMATE PHYSICS AND CHEMISTRY AT THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY SEPTEMBER 2011 © 2011 Massachusetts Institute of Technology. All rights reserved. Signature of Author: _____________________________________________________________ Department of Earth, Atmospheric, and Planetary Sciences 19 August 2011 Certified by: ___________________________________________________________________ Ronald G. Prinn TEPCO Professor of Atmospheric Chemistry Thesis Supervisor Certified by: ___________________________________________________________________ Shuhei Ono Assistant Professor Thesis Co-Supervisor Accepted by: ___________________________________________________________________ Maria T. Zuber E.A. Griswold Professor of Geophysics and Planetary Science Department Head 2 Nitrous oxide (N2O) isotopic composition in the troposphere: instrumentation, observations at Mace Head, Ireland, and regional modeling by Katherine Ellison Potter Submitted to the Department of Earth, Atmospheric, and Planetary Sciences on 19 August 2011 in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Climate Physics and Chemistry Abstract Nitrous
    [Show full text]
  • The Weekly Shot Biotech Issue a Weekly Summary of Healthcare Industry Valuation and Near-Term Catalysts June 17, 2010
    Small Cap The Weekly Shot Biotech Issue June 17, 2010 A weekly summary of healthcare industry valuation and near-term catalysts The Weekly Shot: Overview and Comment - Small Cap Biotechnology Next week's sector highlights include LGND’s Thursday analyst event at the Eventi - Pharmaceuticals and Large Cap Biotech Hotel in NYC. The company on 6/15 announced updated 2010 revenue guidance of approx $25M, op ex of approx $30M, and expects to finish the year with $30M - Generics and Specialty Pharmaceuticals in cash (vs approx $43M as of 1Q10). Management will likely focus on partner GSK’s progress with add’l trials of Promacta (for ITP), which could potentially expand the drug’s label to Hep C, AML, and MDS (LGND receives <10% royalty from GSK). Investors should focus on pipeline plans following LGND’s opportunistic 2008/09 M&A activity. Key pipeline programs include LGD-4033 (ph.I, SARM candidate from PCOP) and RG7348, partnered with Roche (ph.I, Hep C candidate from MBRX). We do not expect major data announcements at the event. FDA’s Pediatric Drugs Advisory Committee will meet Monday to discuss pediatric safety reviews of multiple approved drugs, including Kogenate, Casodex, Apidra, NovoLog, Arimidex, Desmopressin, Prevacid, Nexium, Aciphex, Priolex, OraVerse, Zemuron, and Suprane . While important from a public safety perspective, we do not anticipate regulatory activity to be announced. Brian Lian, Ph.D. Small caps biotechs rebounded mid-week as elevated volatility continued across 212.500.6646 [email protected] the broader market. Investors are struggling to balance economic data supporting a modest recovery against concerns on EU debt loads, financial reform legislation, and aggressive govt rhetoric on BP’s oil spill.
    [Show full text]
  • Ambient Formaldehyde Measurements Made at A
    Ambient formaldehyde measurements made at a remote marine boundary layer site during the NAMBLEX campaign ? a comparison of data from chromatographic and modified Hantzsch techniques T. J. Still, S. Al-Haider, P. W. Seakins, R. Sommariva, J. C. Stanton, G. Mills, S. A. Penkett To cite this version: T. J. Still, S. Al-Haider, P. W. Seakins, R. Sommariva, J. C. Stanton, et al.. Ambient formaldehyde measurements made at a remote marine boundary layer site during the NAMBLEX campaign ? a comparison of data from chromatographic and modified Hantzsch techniques. Atmospheric Chemistry and Physics, European Geosciences Union, 2006, 6 (9), pp.2711-2726. hal-00295970 HAL Id: hal-00295970 https://hal.archives-ouvertes.fr/hal-00295970 Submitted on 6 Jul 2006 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Atmos. Chem. Phys., 6, 2711–2726, 2006 www.atmos-chem-phys.net/6/2711/2006/ Atmospheric © Author(s) 2006. This work is licensed Chemistry under a Creative Commons License. and Physics Ambient formaldehyde measurements made at a remote marine boundary layer site during the NAMBLEX campaign – a comparison of data from chromatographic and modified Hantzsch techniques T.
    [Show full text]
  • CURRICULUM VITAE MARK DAVID SANCHEZ, MD, FACOG 2454 Mcmullen Booth Rd., Suite 601 Phone: (727) 796­7705
    CURRICULUM VITAE MARK DAVID SANCHEZ, MD, FACOG 2454 McMullen Booth Rd., Suite 601 Phone: (727) 796­7705 CURRENT POSITIONS Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida Department Chair Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida BIRTH DATE and PLACE March 25, 1969, Indianapolis, IN EDUCATION and TRAINING 1999­2002 Fellowship in Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology University of South Florida Tampa, Florida 1995­1999 Obstetrics and Gynecology Residency Department of Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida 1991­1995 Doctor of Medicine University of Florida College of Medicine Gainesville, Florida 1989­1991 Bachelor of Science Major: Biology Minor: History University of South Florida Tampa, Florida WORK EXPERIENCE 2002­2014 Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida 2003­2014 Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida 2003­2014 Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida LICENSES, CERTIFICATIONS, AND EXAMINATIONS 1996 Florida Medical License (Active) 2005 Board Certified Reproductive Endocrinology and Infertility 2004 Board Certified
    [Show full text]
  • CLINICAL REVIEW Management of the Effects of Exposure to Tear
    CLINICAL REVIEW For the full versions of these articles see bmj.com Management of the effects of exposure to tear gas Pierre-Nicolas Carron, Bertrand Yersin Service of Emergency Medicine, Despite the frequent use of riot control agents by Eur- solvent, and delivered with a dispersion vehicle (a University Hospital Center and opean law enforcement agencies, limited information pyrotechnically delivered aerosol or spray University of Lausanne, 1011 exists on this subject in the medical literature. The solution).45 Tear gases are not currently considered as Lausanne CHUV, Switzerland Correspondence to: P-N Carron effects of these agents are typically limited to minor chemical weapons by Western countries. Since the [email protected] and transient cutaneous inflammation, but serious 1950s, they have been mainly used by law enforcement complications and even deaths have been reported. agencies for crowd control purposes in most European Cite this as: BMJ 2009;338:b2283 doi:10.1136/bmj.b2283 During the 1999 World Trade Organisation meeting countries, including the United Kingdom, France, and at the 2001 Summit of the Americas in Quebec, Germany, and Switzerland. Tear gases are also used exposure to tear gas was the most common reason for in military training exercises to test the rapidity or effi- medical consultations.12 Primary and emergency care cacy of protective measures in the event of a chemical physicians play a role in the first line management of attack. patients as well as in the identification of those at risk of Of the known disabling chemical irritants (of which complications from exposure to riot control agents.
    [Show full text]